考虑针对COVID-19的个性化干扰素β疗法。 - Suppr

Suppr

超能文献

Considering Personalized Interferon Beta Therapy for COVID-19.

作者信息

Dorgham Karim, Neumann Avidan U, Decavele Maxens, Luyt Charles-Edouard, Yssel Hans, Gorochov Guy

机构信息

Sorbonne Université, Inserm, Centre d'Immunologie et des Maladies Infectieuses (CIMI-Paris), Paris, France

Department of Environmental Medicine, Faculty of Medicine, Universitätsklinikum Augsburg, Augsburg, Germany.

出版信息

Antimicrob Agents Chemother. 2021 Mar 18;65(4). doi: 10.1128/AAC.00065-21.

DOI:10.1128/AAC.00065-21

PMID:33558300

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8097459/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa73/8097459/12d348977cdc/AAC.00065-21-f0001.jpg

相似文献

Considering Personalized Interferon Beta Therapy for COVID-19.考虑针对COVID-19的个性化干扰素β疗法。

Antimicrob Agents Chemother. 2021 Mar 18;65(4). doi: 10.1128/AAC.00065-21.

A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19.一项干扰素 β-1a 治疗重症 COVID-19 的疗效和安全性的随机临床试验。

Antimicrob Agents Chemother. 2020 Aug 20;64(9). doi: 10.1128/AAC.01061-20.

Reply to Dorgham et al., "Considering Personalized Interferon Beta Therapy for COVID-19".对多尔加姆等人《考虑针对新冠肺炎的个性化干扰素β治疗》一文的回复

Antimicrob Agents Chemother. 2021 Mar 18;65(4). doi: 10.1128/AAC.00083-21.

Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan.洛匹那韦/利托那韦未能缩短台湾轻症肺炎患者 SARS-CoV-2 脱落持续时间。

J Microbiol Immunol Infect. 2020 Jun;53(3):488-492. doi: 10.1016/j.jmii.2020.03.032. Epub 2020 Apr 3.

Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review.洛匹那韦/利托那韦治疗严重急性呼吸综合征、中东呼吸综合征和 COVID-19：系统评价。

Eur Rev Med Pharmacol Sci. 2020 Aug;24(16):8592-8605. doi: 10.26355/eurrev_202008_22659.

Conduction abnormalities in hydroxychloroquine add on therapy to lopinavir/ritonavir in COVID-19.在新冠病毒疾病中，羟氯喹与洛匹那韦/利托那韦联合治疗时的传导异常。

J Med Virol. 2020 Nov;92(11):2322-2324. doi: 10.1002/jmv.26004. Epub 2020 May 22.

Lopinavir-ritonavir in severe COVID-19.洛匹那韦-利托那韦治疗重症新型冠状病毒肺炎

Nat Med. 2020 Apr;26(4):465. doi: 10.1038/s41591-020-0849-9.

In COVID-19, adding lopinavir-ritonavir to usual care did not shorten time to clinical improvement.在 COVID-19 中，加用洛匹那韦-利托那韦（lopinavir-ritonavir）联合常规治疗并未缩短临床改善时间。

Ann Intern Med. 2020 Jun 16;172(12):JC63. doi: 10.7326/ACPJ202006160-063.

Crushing lopinavir-ritonavir tablets may decrease the efficacy of therapy in COVID-19 patients.碾碎洛匹那韦-利托那韦片可能会降低其对新冠病毒肺炎患者的治疗效果。

Travel Med Infect Dis. 2020 Nov-Dec;38:101749. doi: 10.1016/j.tmaid.2020.101749. Epub 2020 May 28.

Pharmacokinetics of lopinavir/ritonavir oral solution to treat COVID-19 in mechanically ventilated ICU patients.洛匹那韦/利托那韦口服液治疗 ICU 机械通气 COVID-19 患者的药代动力学。

J Antimicrob Chemother. 2020 Sep 1;75(9):2657-2660. doi: 10.1093/jac/dkaa261.

引用本文的文献

Comparative Toxicity of Interferon Beta-1a Impurities of Heavy Metal Ions.干扰素 β-1a 重金属离子杂质的比较毒性。

Medicina (Kaunas). 2022 Mar 23;58(4):463. doi: 10.3390/medicina58040463.

Exploiting natural antiviral immunity for the control of pandemics: Lessons from Covid-19.利用天然抗病毒免疫来控制大流行：从 COVID-19 中吸取的教训。

Cytokine Growth Factor Rev. 2022 Feb;63:23-33. doi: 10.1016/j.cytogfr.2021.12.001. Epub 2021 Dec 16.

Nasopharyngeal Type-I Interferon for Immediately Available Prophylaxis Against Emerging Respiratory Viral Infections.鼻咽型 I 型干扰素用于即时预防新发呼吸道病毒感染。

Front Immunol. 2021 May 19;12:660298. doi: 10.3389/fimmu.2021.660298. eCollection 2021.

Reply to Dorgham et al., "Considering Personalized Interferon Beta Therapy for COVID-19".对多尔加姆等人《考虑针对新冠肺炎的个性化干扰素β治疗》一文的回复

Antimicrob Agents Chemother. 2021 Mar 18;65(4). doi: 10.1128/AAC.00083-21.

本文引用的文献

Covid-19-Associated Myopathy Caused by Type I Interferonopathy.由I型干扰素病引起的新型冠状病毒肺炎相关性肌病

N Engl J Med. 2020 Dec 10;383(24):2389-2390. doi: 10.1056/NEJMc2031085. Epub 2020 Nov 20.

Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial.吸入用干扰素 β-1a（SNG001）治疗 SARS-CoV-2 感染的安全性和有效性：一项随机、双盲、安慰剂对照、2 期临床试验。

Lancet Respir Med. 2021 Feb;9(2):196-206. doi: 10.1016/S2213-2600(20)30511-7. Epub 2020 Nov 12.

Interferon Beta-1b and Lopinavir-Ritonavir for Middle East Respiratory Syndrome.β-1b 干扰素联合洛匹那韦利托那韦治疗中东呼吸综合征

N Engl J Med. 2020 Oct 22;383(17):1645-1656. doi: 10.1056/NEJMoa2015294. Epub 2020 Oct 7.

Autoantibodies against type I IFNs in patients with life-threatening COVID-19.COVID-19 危重症患者体内针对 I 型干扰素的自身抗体。

Science. 2020 Oct 23;370(6515). doi: 10.1126/science.abd4585. Epub 2020 Sep 24.

Mouse model of SARS-CoV-2 reveals inflammatory role of type I interferon signaling.SARS-CoV-2 小鼠模型揭示了 I 型干扰素信号通路的炎症作用。

J Exp Med. 2020 Dec 7;217(12). doi: 10.1084/jem.20201241.

Longitudinal analyses reveal immunological misfiring in severe COVID-19.纵向分析揭示了重症 COVID-19 中的免疫失调。

Nature. 2020 Aug;584(7821):463-469. doi: 10.1038/s41586-020-2588-y. Epub 2020 Jul 27.

Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients.回顾性多中心队列研究表明，早期干扰素治疗与 COVID-19 患者的良好临床反应相关。

Cell Host Microbe. 2020 Sep 9;28(3):455-464.e2. doi: 10.1016/j.chom.2020.07.005. Epub 2020 Jul 18.

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients.严重 COVID-19 患者的 I 型干扰素活性和炎症反应受损。

Science. 2020 Aug 7;369(6504):718-724. doi: 10.1126/science.abc6027. Epub 2020 Jul 13.

A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19.一项干扰素 β-1a 治疗重症 COVID-19 的疗效和安全性的随机临床试验。

Antimicrob Agents Chemother. 2020 Aug 20;64(9). doi: 10.1128/AAC.01061-20.

Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19.COVID-19 和流感的免疫表型分析突出了 I 型干扰素在 COVID-19 重症发展中的作用。

Sci Immunol. 2020 Jul 10;5(49). doi: 10.1126/sciimmunol.abd1554.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验